Class information for:
Level 1: ADVANCED GASTRIC CANCER//S 1//METASTATIC GASTRIC CANCER

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
4300 1734 31.0 75%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
903 10618 DIHYDROPYRIMIDINE DEHYDROGENASE//5 FLUOROURACIL//THYMIDINE PHOSPHORYLASE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ADVANCED GASTRIC CANCER Author keyword 166 54% 12% 214
2 S 1 Author keyword 149 40% 17% 295
3 METASTATIC GASTRIC CANCER Author keyword 42 66% 2% 39
4 PATHOGEN BIOCHEM MED Address 19 80% 1% 12
5 GASTRIC CANCER Journal 12 14% 4% 78
6 SECOND LINE CHEMOTHERAPY Author keyword 11 19% 3% 53
7 GASTRIC CANCER ADVANCED Author keyword 9 83% 0% 5
8 GIMERACIL Author keyword 8 62% 0% 8
9 LOCALLY ADVANCED GASTRIC CANCER Author keyword 7 57% 0% 8
10 S 1 MONOTHERAPY Author keyword 6 71% 0% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ADVANCED GASTRIC CANCER 166 54% 12% 214 Search ADVANCED+GASTRIC+CANCER Search ADVANCED+GASTRIC+CANCER
2 S 1 149 40% 17% 295 Search S+1 Search S+1
3 METASTATIC GASTRIC CANCER 42 66% 2% 39 Search METASTATIC+GASTRIC+CANCER Search METASTATIC+GASTRIC+CANCER
4 SECOND LINE CHEMOTHERAPY 11 19% 3% 53 Search SECOND+LINE+CHEMOTHERAPY Search SECOND+LINE+CHEMOTHERAPY
5 GASTRIC CANCER ADVANCED 9 83% 0% 5 Search GASTRIC+CANCER++ADVANCED Search GASTRIC+CANCER++ADVANCED
6 GIMERACIL 8 62% 0% 8 Search GIMERACIL Search GIMERACIL
7 LOCALLY ADVANCED GASTRIC CANCER 7 57% 0% 8 Search LOCALLY+ADVANCED+GASTRIC+CANCER Search LOCALLY+ADVANCED+GASTRIC+CANCER
8 S 1 MONOTHERAPY 6 71% 0% 5 Search S+1+MONOTHERAPY Search S+1+MONOTHERAPY
9 OESOPHAGO GASTRIC CANCER 5 54% 0% 7 Search OESOPHAGO+GASTRIC+CANCER Search OESOPHAGO+GASTRIC+CANCER
10 ADVANCED GASTRIC CARCINOMA 5 33% 1% 12 Search ADVANCED+GASTRIC+CARCINOMA Search ADVANCED+GASTRIC+CARCINOMA

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ADVANCED ESOPHAGOGASTRIC CANCER 224 59% 14% 250
2 SUPPORTIVE CARE 76 22% 18% 310
3 PLUS CISPLATIN 61 26% 11% 199
4 ADVANCED GASTRIC CANCER 51 26% 10% 171
5 ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE 49 60% 3% 54
6 CONTINUOUS INFUSION 5 FLUOROURACIL 42 50% 3% 60
7 V 325 STUDY GROUP 42 76% 2% 29
8 GASTROESOPHAGEAL ADENOCARCINOMA 40 54% 3% 52
9 S 1 PLUS CISPLATIN 28 56% 2% 35
10 ORAL FLUOROPYRIMIDINE 27 41% 3% 52

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 GASTRIC CANCER 12 14% 4% 78

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Current questions for the treatment of advanced gastric cancer 2013 29 44 82%
Chemotherapy of advanced gastric cancer 2007 76 38 92%
Chemotherapy for advanced gastric cancer 2010 76 114 67%
Is there a role for second-line chemotherapy in advanced gastric cancer? 2009 51 61 80%
Palliative chemotherapy for advanced gastric cancer 2004 92 93 89%
Optimal chemotherapy for advanced gastric cancer: is there a global consensus? 2014 10 58 76%
The Role of Chemotherapy in Metastatic Gastric Cancer 2011 24 77 97%
Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects 2015 2 43 26%
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis 2013 11 48 92%
Advanced gastric cancer - Slow but steady progress 2010 40 80 73%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PATHOGEN BIOCHEM MED 19 80% 0.7% 12
2 YOUNG LEADERS PROGRAM 5 37% 0.6% 11
3 EPIDEMIOL CLIN INFORMAT MANAGEMENT 5 26% 0.9% 16
4 GASTROINTESTINAL ONCOL DIGEST ENDOSCOPY 3 24% 0.7% 12
5 WUXI CANC HOSP 3 100% 0.2% 3
6 P ALLERGY RHEUMAT DIS 2 67% 0.1% 2
7 P ORGANS 2 67% 0.1% 2
8 TOYOSU HOSP 2 14% 0.6% 10
9 CLIN TRIAL PROMOT 1 38% 0.2% 3
10 FALCK 1 100% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000208946 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY
2 0.0000157299 EARLY GASTRIC CANCER//GASTRECTOMY//D2 LYMPHADENECTOMY
3 0.0000120325 OXALIPLATIN//CAPECITABINE//IRINOTECAN
4 0.0000116764 CARCINOCYTHEMIA//BONE MARROW CARCINOSIS//TUMOR BIOL METASTASIS BRANCH
5 0.0000097087 PERITONEAL LAVAGE CYTOLOGY//J AN FOOD EDUC HLTH//PERITONEAL CYTOLOGY
6 0.0000078899 THYMIDYLATE SYNTHASE//DIHYDROPYRIMIDINE DEHYDROGENASE//OROTATE PHOSPHORIBOSYL TRANSFERASE
7 0.0000075672 BIOCHEMICAL MODULATION//LEUCOVORIN//FOLINIC ACID
8 0.0000051248 NON COLORECTAL//STAGE IV BREAST CANCER//NON NEUROENDOCRINE
9 0.0000048709 DIHYDROPYRIMIDINE DEHYDROGENASE//DPYD//DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY
10 0.0000043695 ADVANCED PANCREATIC CANCER//FOLFIRINOX//METASTATIC PANCREATIC CANCER